Caglar Kayhan, Aybay Cemalettin, Ataoglu Haluk
Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
APMIS. 2005 Apr;113(4):256-63. doi: 10.1111/j.1600-0463.2005.apm_03.x.
Monophosphoryl lipid A (MPL) was evaluated for its ability to enhance the antibody response to diphtheria toxin and its fragment A and fragment B subunits. BALB/c mice were immunized subcutaneously with 1 Lf of diphtheria toxoid in the presence of 25 microg of MPL on days 0 and 14. Two weeks after the second immunization, sera were obtained from the mice and analysed for antibody response to diphtheria toxin and its subunits. A new ELISA method, developed in our laboratory, was used to measure antibody levels against the toxin, fragment A, and fragment B. It was observed that MPL significantly enhanced antibody responses to diphtheria toxin and its subunits. However, there was no statistical difference between anti-A and anti-B responses. The results indicated that MPL seems to be a potential candidate as an adjuvant for future diphtheria vaccine formulation.
评估了单磷酰脂质A(MPL)增强对白喉毒素及其A片段和B片段亚基抗体反应的能力。在第0天和第14天,将1Lf白喉类毒素与25μg MPL一起皮下免疫BALB/c小鼠。第二次免疫两周后,从小鼠中获取血清,并分析对白喉毒素及其亚基的抗体反应。使用我们实验室开发的一种新的ELISA方法来测量针对毒素、A片段和B片段的抗体水平。观察到MPL显著增强了对白喉毒素及其亚基的抗体反应。然而,抗A和抗B反应之间没有统计学差异。结果表明,MPL似乎是未来白喉疫苗配方中一种潜在的佐剂候选物。